Email updates

Keep up to date with the latest news and content from BMC Nephrology and BioMed Central.

Open Access Case report

Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?

Beatriz Fernandez-Fernandez1, Alberto Ortiz12, Carmen Gomez-Guerrero2, Antonio Barat3, Catalina Martín-Cleary1 and Jesús Egido124*

Author Affiliations

1 Nephrology, IIS-Fundacion Jimenez-Diaz, Autonoma University Madrid, Spain

2 Renal and Vascular Research Laboratory, IIS- Fundación Jimenez Díaz. Autonoma University Madrid, Madrid, Spain

3 Pathology division , Fundación Jimenez- Díaz, Madrid, Spain

4 IIS-Fundación Jiménez Díaz, Avda, Reyes Católicos 2, 28040, Madrid, Spain

For all author emails, please log on.

BMC Nephrology 2012, 13:21  doi:10.1186/1471-2369-13-21

Published: 25 April 2012

Abstract

Background

Dual renin-angiotensin system blockade with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been advocated to minimize proteinuria. However, recent trials have questioned the renal safety of this approach. Our understanding on the molecular effects of dual blockade in humans is incomplete.

Case presentation

We present a patient with corticoid resistant nephrotic syndrome who developed marked juxtaglomerular apparatus hyperplasia and renin expression in the context of dual angiotensin system blockade.

Conclusions

Although renin may have profibrotic effects mediated by (pro)renin receptor activation, this report raises questions on the potential consequences of local renin activation on chronic kidney disease in patients with dual angiotensin blockade.

Keywords:
Angiotensin; Juxtaglomerular apparatus hyperplasia; Nephrotic syndrome; Paricalcitol; Renin